John William Jacobs
Chief Tech/Sci/R&D Officer at Phage Biotechnology Corp.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel C. Montano | M | 75 |
Cardio Phage International, Inc.
Venturis Therapeutics, Inc.
 Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.
Phage Biotechnology Corp.
 Phage Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Phage Biotechnology Corp. manufactures protein pharmaceuticals including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies. It also develops biopharmaceuticals whose patents expire. The company was founded in 1998 and is headquartered in Las Vegas, NV. | 26 years |
| Mickael Flaa | M | 71 |
Cardio Phage International, Inc.
Phage Biotechnology Corp.
Phage Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Phage Biotechnology Corp. manufactures protein pharmaceuticals including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies. It also develops biopharmaceuticals whose patents expire. The company was founded in 1998 and is headquartered in Las Vegas, NV.
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 21 years |
| Calvin A. Wallen | M | 68 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 10 years |
| Jon Stuart Ross | M | 59 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 10 years |
| Robert W. Schleizer | M | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 10 years |
| Judith S. Pelton | F | - |
Phage Biotechnology Corp.
Phage Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Phage Biotechnology Corp. manufactures protein pharmaceuticals including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies. It also develops biopharmaceuticals whose patents expire. The company was founded in 1998 and is headquartered in Las Vegas, NV. | - |
| Grant Gordon | M | 62 |
Cardio Phage International, Inc.
| - |
| James R. Richards | M | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 10 years |
| Alfred C. Moran | M | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 10 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andrew Bursky | M | 67 |
Washington University in St. Louis
| 5 years |
| Stuart Thomas Freeman | M | - |
Washington University in St. Louis
| 5 years |
| Steve Joenk | M | - |
Washington University in St. Louis
| 5 years |
| Thomas J. Stegmann | M | 77 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 11 years |
| Gary Abromovitz | M | 81 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 7 years |
| Alan Bender | M | - |
Washington University in St. Louis
| 4 years |
| Gregory Sullivan | M | - |
Washington University in St. Louis
| 4 years |
| Allan J. Young | M | 68 |
Washington University in St. Louis
| 3 years |
| Robert S. Schwartz | M | - |
Washington University in St. Louis
| 3 years |
| Mark Kastan | M | - |
Washington University in St. Louis
| 4 years |
| Gary Cohen | M | - |
Washington University in St. Louis
| 4 years |
| Mark A. Mintun | M | - |
Washington University in St. Louis
| 4 years |
| Chris Varvares | M | - |
Washington University in St. Louis
| 4 years |
| Brian Ruder | M | 51 |
Washington University in St. Louis
| 4 years |
| Erik Swensson | M | 70 |
Washington University in St. Louis
| 3 years |
| Cheryl L. Nesler | M | - |
Washington University in St. Louis
| 4 years |
| Mike McGoey | M | - |
Washington University in St. Louis
| 4 years |
| Jody Vanderwel | F | - |
Washington University in St. Louis
| 3 years |
| Rick A. Kaufman | M | - |
Washington University in St. Louis
| 3 years |
| Scott A. Sterling | M | - |
Washington University in St. Louis
| 4 years |
| Gordon Holt | M | - |
Washington University in St. Louis
| 4 years |
| Shawn Mahoney | M | - |
Washington University in St. Louis
| 4 years |
| William Browning | M | - |
Washington University in St. Louis
| 4 years |
| Robert Blackburn | M | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
| Ernest C. Montano | M | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
| Viktoriya T. Montano | F | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
| Ernest Montano | M | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
| David B. Jones | M | - |
Washington University in St. Louis
| 3 years |
| John Mandelker | M | - |
Washington University in St. Louis
| 4 years |
| Alan Edward Rosenfield | M | - |
Washington University in St. Louis
| 4 years |
| Chris Henry Pauli | M | 67 |
Washington University in St. Louis
| 4 years |
| Jim Weddle | M | 70 |
Washington University in St. Louis
| 2 years |
| John Dacey | M | 64 |
Washington University in St. Louis
| 4 years |
| Bill Marshall | M | - |
Washington University in St. Louis
| 7 years |
| Avram Glazer | M | 63 |
Washington University in St. Louis
| 4 years |
| Arnold Donald | M | 69 |
Washington University in St. Louis
| 4 years |
| Charles Kim | M | 63 |
Washington University in St. Louis
| 4 years |
| Roger Perlmutter | M | 71 |
Washington University in St. Louis
| 3 years |
| William J. Hasek | M | 67 |
Washington University in St. Louis
| 4 years |
| James Earl | M | 67 |
Washington University in St. Louis
| 4 years |
| Alexander Gene Montano | M | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
| William Douglas Black | M | - |
Washington University in St. Louis
| 4 years |
| Frédéric M. Chanson | M | 69 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
| Gilbert R. Whitaker | M | 92 |
Washington University in St. Louis
| 10 years |
| Robert Spinner | M | - |
Washington University in St. Louis
| 2 years |
| Thomas J. Hillman | M | - |
Washington University in St. Louis
| 2 years |
| Bob Derrington | M | - |
Washington University in St. Louis
| 2 years |
| Karen Case | F | 65 |
Washington University in St. Louis
| 4 years |
| Paul Cleveland | M | 67 |
Washington University in St. Louis
| 4 years |
| Larry Macks | M | - |
Washington University in St. Louis
| 4 years |
| Joong-Ki Baik | M | 69 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 9 years |
| Thomas L. Ingram | M | 69 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
| Robert Levin | M | 92 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
| Will K. Bixby | M | - |
Washington University in St. Louis
| 3 years |
| Karen Sheriff | F | 66 |
Washington University in St. Louis
| 4 years |
| David E. Nelson | M | - |
Washington University in St. Louis
| 2 years |
| David A. Weiss | M | - |
Washington University in St. Louis
| 4 years |
| Michael Holmes | M | 65 |
Washington University in St. Louis
| 3 years |
| Mike Norris | M | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
| Andrew Franklin Puzder | M | 73 |
Washington University in St. Louis
| 3 years |
| Sandra Moore | F | - |
Washington University in St. Louis
| - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 69 | 98.57% |
| Bahamas | 3 | 4.29% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John William Jacobs
- Personal Network
